# DESCRIPTION

## BACKGROUND

- introduce brain water homeostasis
- describe importance of ion transport
- discuss role of CCCs in CNS regulation
- explain SPAK/OSR1 regulation of CCCs
- highlight importance of SPAK-regulated CCCs in brain pathologies
- discuss need for compounds modulating CCCs

## SUMMARY

- introduce N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)ben
- describe compounds having a specific structure
- disclose pharmaceutical compositions
- outline methods for treating hypoxic brain injuries
- outline methods for modifying SPAK kinase function
- disclose kits comprising compounds

## DETAILED DESCRIPTION

- set scope and terminology
- clarify patent interpretation

### A. Definitions

- define singular forms
- define ranges with "about"
- define parts by weight
- define weight percent
- define "optional" or "optionally"
- define "subject"
- define "treatment"
- define "prevent" or "preventing"
- define "diagnosed"
- define "administering" and "administration"
- define "treating"
- define "contacting"
- define "effective amount" and "amount effective"
- define "IC50"
- define "comprising"
- define "derivatives"
- define alkyl
- define cycloalkyl
- define polyalkylene group
- define alkoxy
- define alkenyl
- define cycloalkenyl
- define alkynyl
- define cycloalkynyl
- define aryl
- define aldehyde
- define amine
- define carboxylic acid
- define ester
- define azide
- define nitro
- define nitrile
- define silyl
- define sulfo-oxo
- define thiol
- describe R1, R2, R3, Rn
- describe optionally substituted moieties
- define stable
- list suitable monovalent substituents
- list suitable divalent substituents
- describe substituents on R*
- describe substituents on Râ€ 
- define organic residue
- define radical
- describe inorganic radicals
- define enantiomers and racemic mixtures
- describe methods for resolving enantiomers
- define enantiomeric excess
- describe diastereoisomers and methods for separating them
- discuss isotopically-labeled compounds and their uses
- describe solvates and hydrates
- define co-crystals
- discuss polymorphic forms of compounds
- describe representation of compound structures using formulas
- discuss availability of starting materials and reagents
- clarify order of steps in methods
- describe scope of disclosed materials and methods

### B. Compounds

- introduce compounds for treating SPAK kinase function disorders
- describe modification of SPAK kinase function
- describe inhibition of SPAK kinase function
- describe use in inhibiting SPAK kinase function in a mammal
- describe use in inhibiting SPAK kinase function in at least one cell
- describe use in treating hypoxic brain injuries
- define compound structure
- specify R1 groups
- specify R2A, R2B, R2C, and R2D groups
- specify R20 groups
- specify R21a and R21b groups
- provide example compounds

### C. Pharmaceutical Compositions

- define pharmaceutical compositions
- pharmaceutical composition comprising at least one disclosed compound
- pharmaceutical composition comprising a therapeutically effective amount
- pharmaceutical composition comprising a prophylactically effective amount
- pharmaceutical composition comprising a pharmaceutically acceptable carrier
- examples of suitable aqueous and nonaqueous carriers
- formulations suitable for oral administration
- formulations suitable for parenteral administration
- formulations suitable for topical administration
- formulations suitable for rectal administration
- formulations suitable for vaginal administration
- administration to a mammal
- administration following identification of need for treatment
- administration following diagnosis of cancer
- administration following diagnosis of fibrotic disorder
- administration following diagnosis of need for immunotherapy
- choice of carrier determined by method of administration

### D. Methods of Making the Compounds

- methods of making N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl
- compounds prepared by synthetic methods outlined
- pharmaceutical composition comprising a therapeutically effective amount

### E. Methods of Using the Compounds

- introduce compounds and pharmaceutical compositions
- describe treating or controlling conditions or disorders associated with SPAK kinase function
- specify subjects in need of treatment
- describe administration methods
- specify dosage and frequency
- describe treatment methods for hypoxic brain injuries
- specify hypoxic brain injuries caused by traumatic brain injury or ischemic stroke
- describe identifying subjects in need of treatment
- describe administering therapeutically effective amounts of compounds
- specify compounds having a specific structure
- describe modifying SPAK kinase function in a subject
- specify decreasing or inhibiting SPAK kinase function
- describe identifying subjects in need of modifying SPAK kinase function
- describe modifying SPAK kinase function in at least one cell
- specify contacting cells with effective amounts of compounds
- describe decreasing or inhibiting SPAK kinase function in cells
- specify uses of compounds for treating disorders or conditions
- describe manufacturing medicaments for treating hypoxic brain injuries
- specify combining compounds with pharmaceutically acceptable carriers or diluents
- describe kits comprising compounds and agents associated with treating hypoxic brain injuries
- specify instructions for administering compounds and treating hypoxic brain injuries
- describe co-formulating or co-packaging compounds and agents
- describe preparing kits from disclosed compounds and pharmaceutical compositions

### F. Examples

- disclose dual CCC modulator ZT-1a
- describe general chemistry experimental methods
- outline general synthesis of compounds 1a-1j
- prepare 5-chloro-2-hydroxybenzoyl chloride (I-1a)
- synthesize 5-chloro-N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2
- synthesize N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)-
- synthesize N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)
- synthesize 3,5-dichloro-N-(5-chloro-4-((4-chlorophenyl)(cyano)m
- describe compound synthesis
- describe compound synthesis
- describe compound synthesis
- describe compound synthesis
- outline general biology experimental methods
- describe plasmid preparation and protein expression
- describe SPAK kinase assays and IC50 determination
- describe fluorescence polarization measurements
- describe pharmacodynamic study
- describe cell culture, transfections, and stimulations
- describe 86Rb+ uptake assay in HEK293 cells
- model post-hemorrhagic hydrocephalus
- quantify CSF production and intracerebroventricular drug administration
- harvest and isolate choroid plexus tissue
- induce middle cerebral artery occlusion
- measure cerebral blood flow
- measure brain infarction volume and hemispheric swelling
- assess neurological deficit score
- perform corner test
- perform adhesive removal test
- perform DTI of ex-vivo brains
- prepare brain membrane and cytosolic protein fractions
- describe animal preparation
- induce focal ischemic stroke and reperfusion
- determine ZT-1a pharmacokinetic properties
- induce Ang II-mediated hypertension and measure blood pressure
- induce focal cerebral ischemia with permanent middle cerebral artery occlusion
- administer drug treatment in HTN mice
- measure brain infarction volume and hemispheric swelling in HTN mice
- assess neurological function tests in HTN mice
- describe experimental design
- motivate statistical analysis
- identify ZT-1a as SPAK inhibitor
- describe hybrid design strategy
- test ZT-1a potency
- analyze ZT-1a kinase selectivity
- disrupt SPAK interaction with WNK
- analyze ZT-1a binding site
- test ZT-1a effect on SPAK-WNK interaction
- present kinetic data for ZT-1a
- show ZT-1a reduces CCC phosphorylation
- demonstrate ZT-1a promotes KCC-dependent Cl- extrusion
- describe SPAK inhibitory effects of ZT-1a on CCC phosphorylation
- present in vivo pharmacodynamic analysis of ZT-1a
- show ZT-1a pharmacokinetics
- demonstrate ICV delivery of ZT-1a normalizes CSF hypersecretion
- show effect of ZT-1a on IVH-induced phosphorylation of SPAK/OSR1, NKCC1, KCC2,
- demonstrate effect of ZT-1a on IVH-induced CSF hypersecretion
- show post-stroke administration of ZT-1a reduces ischemic cerebral edema
- present experimental design of ischemic stroke study
- show representative images and quantification of infarct volume and hemispheric swelling
- introduce ZT-1a's effect on neurological function deficits
- evaluate neurobehavioral tests
- show neurological deficit scores
- describe corner test results
- describe adhesive contact and removal tests
- inhibit SPAK-NKCC1 phospho-activation
- test phosphorylation of SPAK/OSR1, NKCC1, and KCC3
- prevent ischemia-induced increases of pSPAK/pOSR1, pNKCC1, and pKCC3
- exhibit persistent protection of grey and white matter
- conduct ex vivo MRI studies
- analyze fractional anisotropy, axial diffusivity, radial diffusivity, and mean diffusivity
- compare neuroprotective efficacy of Closantel and WNK463
- describe superiority of ZT-1a to WNK463 and Closantel
- summarize ZT-1a's neuroprotective effects
- discuss limitations of bumetanide and furosemide
- introduce ZT-1a as a novel effective kinase-cotransporter modulator
- describe CSF production
- motivate TLR4-dependent activation
- summarize ZT-1a's therapeutic potential
- introduce ZT-1a's brain penetration
- describe SPAK inhibitor's effect on infarct volume
- summarize ZT-1a's effect on neurological deficits
- describe behavioral tests
- conclude with invention's scope

